# Larkspur Biosciences

Source: https://onco.cc/companies/larkspur-biosciences/  
OnCo record `larkspur-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Larkspur Biosciences makes medicines that remove proteins tumours rely on to survive stress. Its first medicine, taken daily, is being tested in solid tumours with a focus on bowel cancer, alone and with chemotherapy.

## Summary

Larkspur Biosciences Inc., at One Canal Park, Cambridge, Massachusetts, develops first-in-class protein degraders aimed at stress-response pathways that tumours depend on, according to its website. Its lead LRK-4189, taken daily, is in a phase 1b/2 dose-escalation, expansion and optimisation trial (NCT07498725) alone and with mFOLFOX6 or FOLFIRI in solid tumours with a focus on colorectal cancer, at sites in Edinburgh, Nice and Strasbourg. Its first registered cancer trial, NCT07498725, was posted on ClinicalTrials.gov in March 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Cambridge, MA
- Type: biotech
- Website: https://larkspur.bio/

## Notes

- Read on 29 October 2026 through a fetch summary because the site refused a plain request (HTTP 403). The website does not name the target of LRK-4189, and the registry record does not either, so no target is recorded.
- Founding year, investors and financing were not stated on the page read.

## Sources

- Official website: https://larkspur.bio/

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- trials: [A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors](https://onco.cc/trials/nct07498725/)

---
JSON: https://onco.cc/api/v1/entities/larkspur-biosciences.json